Emergomycosis
| Emergomycosis | |
|---|---|
| Other names | Emmonsiosis |
| A conidiospore of Emergomyces orientalis, from a Tibetan man with emergomycosis | |
| Specialty | Infectious diseases |
| Symptoms | Skin rash |
| Causes | Emergomyces, previously classified under genus Emmonsia |
| Risk factors | HIV, organ transplant, steroid use. |
| Diagnostic method | skin biopsy, histopathology |
| Differential diagnosis | Histoplasmosis |
| Treatment | Antifungals |
| Medication | Amphotericin B |
| Frequency | Rare |
Emergomycosis, previously known as emmonsiosis, is a systemic dimorphic fungal infection that can affect multiple organs, generally always affects the skin, and can become widespread. It is endemic to South Africa and primarily affects individuals with HIV/AIDS and other immunocompromised people, although it can also infect people with healthy immune systems. The lesions in the skin look like small red bumps and patches with a dip, ulcer and dead tissue in the centre.
It is caused by the Emergomyces species, a novel dimorphic fungus, previously classified under the genus Emmonsia. These fungi are found in soil and transmitted by breathing in its spores from the air. Inside the body it converts to yeast-like cells which then cause disease and invade beyond the lungs. Diagnosis is by skin biopsy and its appearance under the microscope. It is difficult to distinguish from histoplasmosis.
Treatment is usually with amphotericin B. Emergomycosis can be fatal.
Emergomycosis is rare. The disseminated type is more prevalent in South Africa, particularly in people with HIV. The disease is named for Chester Wilson Emmons who first described Emmonsia.